Last reviewed · How we verify
Combination, Palbociclib + Binimetinib (combination-palbociclib-binimetinib)
At a glance
| Generic name | combination-palbociclib-binimetinib |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 1 |
Approved indications
Common side effects
- Platelet count decreased
- Rash acneiform
- Neutrophil count decreased
- Fatigue
- Anemia
- Nausea
- Diarrhoea
- Asthenia
- White blood cell decreased
- Vomiting
- Aspartate aminotransferase increased
- CPK increased
Key clinical trials
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial (PHASE2)
- Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer (PHASE1)
- Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer (PHASE1, PHASE2)
- Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer (PHASE2)
- Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE (PHASE1, PHASE2)
- Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |